Heartflow, INC

Heartflow, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of Class I directors and the ratification of PricewaterhouseCoopers LLP as its independent auditor.

Heartflow, Inc. reported robust financial results for the fourth quarter and full year ended December 31, 2025, driven by accelerating adoption of its AI technology for coronary artery disease.

Heartflow, Inc. presented robust financial performance, significant advancements in AI-powered coronary artery disease diagnostics, and strategic plans for market expansion at an investor conference.

Heartflow, Inc. announced a 41% year-over-year revenue increase in Q3 2025, alongside initiating full-year 2025 revenue guidance and highlighting key operational advancements.

Heartflow, Inc. announced preliminary unaudited financial results for Q2 2025, including revenue of $43.4 million and a gross margin of 75.5%, alongside an update on its cash position and recent IPO proceeds.

Heartflow, Inc. announced the full prepayment and termination of its Credit Agreement, settling $61.1 million in outstanding debt without incurring fees.

Heartflow, Inc. announced a 41% revenue increase in Q3 2025, driven by higher case volumes, and significantly improved its cash position following its August 2025 IPO, despite continued net losses and a new DOJ investigation.

Heartflow, Inc. reported a 40% revenue increase in Q2 2025, driven by higher case volumes, as it transitioned to a public company following its August 2025 IPO.

John C.M. Farquhar, Chief Executive Officer and a Director of Heartflow, Inc., reported multiple transactions in common stock on July 30, 2026.

Vikram Verghese, Chief Financial Officer of Heartflow, Inc., reported multiple transactions in common stock on July 27, 2026.

Jeffrey C Lightcap, a Director of Heartflow, Inc., reported multiple transactions in common stock on July 24, 2026.

Timothy C Barabe, a Director of Heartflow, Inc., reported multiple transactions in common stock on July 22, 2026.

Vikram Verghese, Chief Financial Officer of Heartflow, Inc., reported multiple transactions in common stock on July 21, 2026.

Timothy C Barabe, a Director of Heartflow, Inc., reported multiple transactions in common stock on July 17, 2026.

Heartflow, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026, to elect directors and ratify the appointment of its independent auditor.

Heartflow, Inc. files for an initial public offering of 16.67 million shares at $17.00-$18.00 to fund growth in its AI-driven coronary artery disease diagnostic platform.

HeartFlow, Inc., a pioneer in AI-powered coronary artery disease diagnosis, files for an initial public offering of 12.5 million shares, targeting a price range of $15.00 to $17.00 per share.

Heartflow, a pioneer in AI-powered coronary artery disease diagnostics, has filed its S-1 registration statement for an initial public offering, showcasing significant revenue growth and an expanding product pipeline despite ongoing net losses.

Several Hayfin entities have reported a reduction in their beneficial ownership of HeartFlow, Inc. Class A Common Stock, with aggregate holdings now below 5% for some.

HealthCor Partners Management LP and its affiliated funds reported a significant reduction in their beneficial ownership of Heartflow, Inc. common stock following a distribution to fund investors.

Wellington Management Group and its affiliates reported a 14.0% beneficial ownership in Heartflow, Inc.'s common stock.

Wellington Management Group LLP and its affiliates have reported a 6.9% beneficial ownership stake in Heartflow, Inc. common stock.

HealthCor Partners Management LP and affiliated funds have reported a 7.9% beneficial ownership stake in Heartflow, Inc., totaling 6,697,556 common shares.

BCLS Fund III Investments, LP, a Bain Capital Life Sciences entity, has reported a 14.9% beneficial ownership stake in Heartflow, Inc., holding 12,448,158 shares of common stock.